A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non–Hodgkin's Lymphoma: A Children's Oncology Group Study

Phase II Study of Mitoguazone, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone for Patients with Diffuse Histologic Subtypes of Non-Hodgkin's Lymphoma: An Eastern Cooperative Oncology Group Study (PE481)

Leukemia & Lymphoma ◽

10.3109/10428199809057572 ◽

1998 ◽

Vol 30 (5-6) ◽

pp. 601-607 ◽

Cited By ~ 7

Author(s):

Peter H. Wiernik ◽

Dirk F. Moore ◽

John M. Bennett ◽

Steven E. Vogl ◽

Jules E. Harris ◽

...

Keyword(s):

Phase Ii ◽

Hodgkin’S Lymphoma ◽

Phase Ii Study ◽

Eastern Cooperative Oncology Group ◽

Hodgkin's Lymphoma ◽

Oncology Group ◽

Oncology Group Study ◽

Non Hodgkin's Lymphoma ◽

Histologic Subtypes

Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma

European Journal of Nuclear Medicine and Molecular Imaging ◽

10.1007/s002590000276 ◽

2000 ◽

Vol 27 (7) ◽

pp. 766-777 ◽

Cited By ~ 164

Author(s):

Gregory A. Wiseman ◽

Christine A. White ◽

Michael Stabin ◽

William L. Dunn ◽

William Erwin ◽

...

Keyword(s):

Phase I ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Ibritumomab Tiuxetan ◽

Non Hodgkin's Lymphoma ◽

Yttrium 90

Phase I Study of Fludarabine and Paclitaxel for the Treatment of Low-Grade Non-Hodgkin's Lymphoma

Leukemia & Lymphoma ◽

10.3109/10428199709109160 ◽

1997 ◽

Vol 26 (1-2) ◽

pp. 77-82 ◽

Cited By ~ 7

Author(s):

Anas Younes ◽

Maria A. Rodriguez ◽

Peter McLaughlin ◽

Luceil North ◽

Andreas H. Sarris ◽

...

Keyword(s):

Phase I ◽

Phase I Study ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Low Grade ◽

Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG)

Leukemia & Lymphoma ◽

10.1080/10428190600709226 ◽

2006 ◽

Vol 47 (10) ◽

pp. 2140-2146 ◽

Cited By ~ 75

Author(s):

George Papaxoinis ◽

Sotirios Papageorgiou ◽

Dimitra Rontogianni ◽

Vassiliki Kaloutsi ◽

George Fountzilas ◽

...

Keyword(s):

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Oncology Group ◽

Oncology Group Study ◽

Clinicopathologic Study ◽

Phase I Study of Bryostatin-1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma

Clinical Lymphoma ◽

10.3816/clm.2002.n.025 ◽

2002 ◽

Vol 3 (3) ◽

pp. 184-188 ◽

Cited By ~ 7

Author(s):

John D. Roberts ◽

Mitchell R. Smith ◽

Eric J. Feldman ◽

Louise Cragg ◽

Steven Grant

Keyword(s):

Chronic Lymphocytic Leukemia ◽

Phase I ◽

Phase I Study ◽

Hodgkin’S Lymphoma ◽

Lymphocytic Leukemia ◽

Hodgkin's Lymphoma ◽

Bryostatin 1 ◽

The combination of gemcitabine plus vinorelbine as salvage treatment in non-Hodgkin's Lymphoma. A hellenic cooperative oncology group study

European Journal of Cancer ◽

10.1016/s0959-8049(01)80834-0 ◽

2001 ◽

Vol 37 ◽

pp. S95 ◽

Cited By ~ 2

Author(s):

C. Nicolaides ◽

T. Economopoulos ◽

M.A. Demopoulos ◽

E. Samantas ◽

D. Skarlos ◽

...

Keyword(s):

Hodgkin’S Lymphoma ◽

Salvage Treatment ◽

Hodgkin's Lymphoma ◽

Oncology Group ◽

Oncology Group Study ◽

Correction: The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-2913 ◽

2010 ◽

Vol 16 (4) ◽

pp. 1343-1343

Keyword(s):

Phase I ◽

Hodgkin’S Lymphoma ◽

Phase I Trial ◽

Hodgkin's Lymphoma ◽

The Novel ◽

Ibritumomab Tiuxetan ◽

Motexafin Gadolinium ◽

Non Hodgkin's Lymphoma ◽

Expanded Porphyrin

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-09-0905 ◽

2009 ◽

Vol 15 (20) ◽

pp. 6462-6471 ◽

Cited By ~ 9

Author(s):

Andrew M. Evens ◽

William G. Spies ◽

Irene B. Helenowski ◽

David Patton ◽

Stewart Spies ◽

...

Keyword(s):

Phase I ◽

Hodgkin’S Lymphoma ◽

Phase I Trial ◽

Hodgkin's Lymphoma ◽

The Novel ◽

Ibritumomab Tiuxetan ◽

Motexafin Gadolinium ◽

Non Hodgkin's Lymphoma ◽

Expanded Porphyrin

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

Annals of Oncology ◽

10.1016/j.annonc.2020.03.294 ◽

2020 ◽

Vol 31 (6) ◽

pp. 780-788 ◽

Cited By ~ 2

Author(s):

V. Moreno ◽

J.M. Sepulveda ◽

M. Vieito ◽

T. Hernández-Guerrero ◽

B. Doger ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Advanced Solid Tumors ◽

Bet Inhibitor ◽

Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809

Annals of Oncology ◽

10.1093/annonc/mdq619 ◽

2011 ◽

Vol 22 (6) ◽

pp. 1382-1391 ◽

Cited By ~ 20

Author(s):

K. Ohmachi ◽

K. Tobinai ◽

Y. Kobayashi ◽

K. Itoh ◽

M. Nakata ◽

...

Keyword(s):

Clinical Oncology ◽

Hodgkin’S Lymphoma ◽

Hodgkin's Lymphoma ◽

Phase Iii ◽

Oncology Group ◽

Japan Clinical Oncology Group ◽

Phase Iii Trial ◽

Oncology Group Study ◽